Molbio Diagnostics Limited has announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company’s Board of Directors approved the standalone and consolidated financial statements. Key highlights include the approval of un-audited financial results and a limited review report, along with the monitoring agency report on IPO proceeds. The company also noted the resignation of Dr. Kuldeep Singh Sachdeva and appointed new secretarial auditors.
Molbio Diagnostics Announces Q2 FY27 Financial Results
Molbio Diagnostics Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2026. The announcement was made following a Board Meeting held on November 05, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Financial Approvals
The Board of Directors has approved the Un-audited Financial Results (Standalone & Consolidated) for the aforementioned period. These results, along with the accompanying Limited Review Report, are enclosed as “Annexure-A”. The Statutory Auditor has issued an unmodified opinion on these financial statements.
Monitoring Agency Report and IPO Proceeds
An approval was also granted for the Monitoring Agency Report concerning the utilization of proceeds from the company’s Initial Public Offer (IPO) for the quarter ended September 30, 2026. This was in accordance with Regulation 32 of the SEBI Listing Regulations and was approved by the Audit Committee.
Leadership and Personnel Changes
The company noted the resignation of Dr. Kuldeep Singh Sachdeva, who held the position of President & Chief Medical Officer, Partnerships and Advocacy. His last working day is scheduled for January 21, 2027. Further, M/s. Rakesh Hulihalli & Associates, a Practising Company Secretaries firm, has been appointed as the Secretarial Auditor for a term of five years, commencing from FY 2026-27.
Postal Ballot and Corporate Governance
The Board also approved the notice for a Postal Ballot, to be conducted through a remote e-voting process. Directors or Key Managerial Personnel have been authorized to determine the cut-off date and dispatch the notice to eligible members.
The financial statements and relevant disclosures will also be available on the company’s website, www.molbiodiagnostics.com, in line with Regulation 46 of the SEBI Listing Regulations.
Source: BSE
